Moderna, Inc. (MRNA) stock was up more than 5% at close on Friday. In fact, there were two potential reasons recently that made investors to watch this stock, and it will affect the future trend of the stock.
Recently, the COVID-19 vaccines of AstraZeneca and Johnson & Johnson are both experiencing issues, and investors predict that Moderna will benefit from it.
Johnson & Johnson has encountered issues with manufacturing the drug. Last week, an error at one contractor’s plant affected 15 million doses worth of a key ingredient in the J&J vaccine, J&J has since taken over control of that plant. So, the Centers for Disease Control and Prevention have allocated just 700,000 doses of the J&J vaccine for the next week, that’s down considerably from this week’s 4.95 million doses.
Meanwhile, the European Medicines Agency on April 7 has concluded that certain unusual types of blood clots are a very rare side effect of the AstraZeneca COVID-19 vaccine, the conclusion may make several countries to alter their immunization rollouts in coming weeks.
Despite these issues do not mean that AstraZeneca and Johnson & Johnson will lose vaccine markets in U.S. and EU, but investors may naturally turn to its competitors in their subconscious mind.
Additionally, Moderna said on wednesday that the new data shows antibody persistence through 6 months following the second dose of Moderna COVID-19 vaccine. The company said this gave them further confidence in the protection afforded by its COVID-19 vaccine and it remains committed to continuing to address the COVID-19 pandemic.
Meanwhile, the company also said that it expects its booster shot targeting coronavirus variants should be available by the end of 2021. At present, the global demand for Covid-19 vaccine is extremely high. Moderna still has a chance to generate strong revenue from its COVID-19 vaccine even if the pandemic is over.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.